In all three datasets, the RIPK2 high expression group and RIPK2 low expression group showed significant differences in survival in terms of OS and PFI, suggesting that high expression of RIPK2 is a risk factor for survival in patients with serous ovarian cancer (Fig. 2). This evidence concerns the gene RIPK2 and ovarian serous adenocarcinoma.